Delayed-release Formulation Evaluation
Delayed-Release Formulation Evaluation is a systematic analytical framework used in pharmaceutical bioequivalence assessment that specifically characterizes the in vitro and in vivo performance of dosage forms designed to release the active ingredient after a predetermined lag period, thereby differentiating them from immediate- and extended-release formulations.
99
Publications
3.7K
Citations
536
Authors
217
Institutions
Publications per year
2017–2026
14
99
Philippe Ruszniewski, Sofia Ish‐Shalom, Machteld Wymenga et al. · Neuroendocrinology · 2004 · 157 citations
Philip Van Kerrebroeck, A Jardin, K.U. Laval et al. · European Urology · 2000 · 150 citations
Marc Roger, Jean‐Louis Chaussain, P. Berlier et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 117 citations
1–5 of 99
536
4
h-index
3
h-index
3
h-index
3
h-index
3
h-index
1–5 of 536
217

Monsanto (United States)
Creve Coeur, United States
6 h-index
33 publications
1.3K citations
Takeda (United States)
Deerfield, United States
5 h-index
22 publications
855 citations
Abbott Fund
Chicago, United States
5 h-index
13 publications
608 citations
Abbott (United Kingdom)
Maidenhead, United Kingdom
4 h-index
5 publications
215 citations
Inserm
Paris, France
3 h-index
6 publications
303 citations

Cornell University
Ithaca, United States
3 h-index
23 publications
1.1K citations
Deerfield (United States)
New York, United States
3 h-index
7 publications
328 citations
University of Washington
Seattle, United States
2 h-index
5 publications
154 citations
1–8 of 217
Repository · 7 publications · 145 citations
7
h-index
6 publications · 376 citations
6
h-index
5 publications · 141 citations
5
h-index
JDS · 4 publications · 155 citations
4
h-index
AJG · 3 publications · 100 citations
3
h-index
1–5